Publications by authors named "Linxiang Zhao"

Claim this Profile
S
Synthesis and biological evaluations of novel 18β-glycyrrhetinic acid derivatives as histone deacetylase 3 degraders with anti-inflammatory effects.
Huanhuan Qin, Rulong Liu, Yue Shi, Bing Wang, Luhao Guo, Linxiang Zhao

Eur J Med Chem· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Thiol esters as chemical warheads of SARS-CoV-2 main protease (3CLpro) peptide-like inhibitors" [Eur. J. Med. Chem. 293 (2025) 117709].
Xuehong Qiao, Menghan Cui, Zhiwei Yu, Ling Ma, Hailong Liu, Linxiang Zhao

Eur J Med Chem· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, Synthesis, and Biological Evaluation of a Series of Novel LFA-1 Antagonists with Enhanced Potency and Ocular Safety for Dry Eye Disease.
Manman Sun, Jie Zhang, Aohui Hu, Jiacheng Wang, Kaile Yao, Linxiang Zhao

J Med Chem· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overcoming venetoclax resistance through heme-mediated NOXA/cyclin D1/Mcl-1 axis with a novel artemisinin conjugate.
Jingyi Zhang, Zhenwei Zhang, Jinghua Liu, Shenglin Luan, Jiqiang Qu, Linxiang Zhao

Blood Adv· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thiol esters as chemical warheads of SARS-CoV-2 main protease (3CLpro) peptide-like inhibitors.
Xuehong Qiao, Menghan Cui, Zhiwei Yu, Ling Ma, Hailong Liu, Linxiang Zhao

Eur J Med Chem· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of TNI-97 as a Highly Selective, Orally Bioavailable HDAC6 Inhibitor for the Treatment of Triple-Negative Breast Cancer.
Siyuan Wang, Meidi Luo, Qihao Xu, Rongxian Guo, Wenchao Zhang, Linxiang Zhao

J Med Chem· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 4,5-dihydro-benzo[g]indazole-based hydroxamic acids as HDAC3/BRD4 dual inhibitors and anti-tumor agents.
Bo Li, Yibing Chen, Siyuan Wang, Bo Jin, Jinyu Yang, Linxiang Zhao

Eur J Med Chem· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unlocking the potential: advancements and future horizons in ROR1-targeted cancer therapies.
Lin Li, Weixue Huang, Xiaomei Ren, Zhen Wang, Ke Ding, Linxiang Zhao

Sci China Life Sci· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of the First BRD4 Second Bromodomain (BD2)-Selective Inhibitors.
Junhua Li, Qingqing Hu, Run Zhu, Ruibo Dong, Hui Shen, Linxiang Zhao

J Med Chem· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization and noncovalent inhibition of the K63-deubiquitinase activity of SARS-cov-2 PLpro.
Xin Liu, Miao Zheng, Hongqing Zhang, Bo Feng, Jiaqi Li, Na Zhao, Linxiang Zhao

Antiviral Res· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Novel Mcl-1 Inhibitors with a 3-Substituted-1-indole-1-yl Moiety Binding to the P1-P3 Pockets to Induce Apoptosis in Acute Myeloid Leukemia Cells.
Hongguang Deng, Jingyi Zhang, Liang Liu, Hong Zhang, Yu Han, Linxiang Zhao

J Med Chem· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and characterization of novel potent non-covalent small molecule inhibitors targeting papain-like protease from SARS-CoV-2.
Miao Zheng, Bo Feng, Yumin Zhang, Xin Liu, Na Zhao, Shizhao Chen, Linxiang Zhao

Acta Pharm Sin B· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, synthesis and biological evaluation of 4-(indolin-1-yl)-6-substituted-pyrido[3,2-d]pyrimidine derivatives as Mnk1/2 inhibitors.
Kun Xing, Huimin Zhang, Shuxiang Wang, Jinghuan Li, Zhiying Mu, Linxiang Zhao

Eur J Med Chem· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Directly targeting BAX for drug discovery: Therapeutic opportunities and challenges.
Zhenwei Zhang, Linghui Hou, Dan Liu, Shenglin Luan, Min Huang, Linxiang Zhao

Acta Pharm Sin B· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting Myeloid Leukemia-1 in Cancer Therapy: Advances and Directions.
Hongguang Deng, Yu Han, Liang Liu, Hong Zhang, Dan Liu, Linxiang Zhao

J Med Chem· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of the synthesis of BET BD2 selective inhibitor XY153.
Run Zhu, Junhua Li, Ruibo Dong, Qingqing Hu, Zhiming Chen, Linxiang Zhao

Chem Biodivers· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Computer-aided drug design course for pharmacy major students in Shenyang Pharmaceutical University following the COVID-19 pandemic: Challenges and opportunities.
Min Huang, Yue Du, Yajing Liu, Yanfang Zhao, Yongxue Guo, Linxiang Zhao

Biochem Mol Biol Educ· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Construction of Diversified Penta-Spiro-Heterocyclic and Fused-Heterocyclic Frameworks with Potent Antitumor Activity.
Qi Liu, Xuyi Liu, Yazhou Li, Yu Zhou, Linxiang Zhao

Chemistry· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Construction of Diversified Penta-Spiro-Heterocyclic and Fused-Heterocyclic Frameworks with Potent Antitumor Activity.
Qi Liu, Xuyi Liu, Yazhou Li, Yu Zhou, Linxiang Zhao

Chemistry· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rational design, synthesis and biological evaluation of benzo[d]isoxazole derivatives as potent BET bivalent inhibitors for potential treatment of prostate cancer.
Junhua Li, Run Zhu, Xiaoxi Zhuang, Cheng Zhang, Hui Shen, Linxiang Zhao

Bioorg Chem· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of BAX trigger site activator BTSA1 with improved antitumor potency and in vitro ADMET properties.
Zhenwei Zhang, Shan Zhao, Jiying Pei, Linghui Hou, Shenglin Luan, Linxiang Zhao

Eur J Med Chem· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis of Paclitaxel Derivatives for Remote Loading into Liposomes and Improved Therapeutic Effect.
Xiangwei Xu, Yanhua Liu, Shanshan Shao, Jinbo Li, Zhaochu Xu, Linxiang Zhao

Molecules· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a series of novel Mcl-1 inhibitors bearing an indole carboxylic acid moiety.
Hongguang Deng, Min Huang, Hui Liu, Hong Zhang, Liang Liu, Linxiang Zhao

Bioorg Chem· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and structure-activity relationship studies of novel Bcl-2/Mcl-1 dual inhibitors with indole scaffold.
Zhenwei Zhang, Linghui Hou, Lijun Bai, Jiying Pei, Shan Zhao, Linxiang Zhao

Bioorg Chem· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa/Bim/Mcl-1/p-Chk1 axis.
Jingyi Zhang, Yuetong Wang, Chujie Yin, Ping Gong, Zhenwei Zhang, Linxiang Zhao

Cell Death Dis· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis